Pα+ Psychedelic Bulletin #174: Psilocybin Outperforms Escitalopram After 6 Months… or Does It? Survey Results Reveal Healthcare Practitioner Attitudes to Psychedelics; and more… – Psychedelic Alpha

In this Issue

Six-Month Follow-Up Data Shows Psilocybin Outperforms Escitalopram… or Does It?
Survey Reveals Healthcare Practitioner Attitudes to Psychedelics
MIND Foundation Plots 700-Patient Psilocybin Study
Beckley Psytech-affiliated Study of Low-Dose Psilocybin for Headache Disorder Terminated Due to Recruitment Difficulties
More Headlines

***

Sign-in or join Pα+ to continue reading this Issue of the Psychedelic Bulletin…

Independent data-driven reporting, analysis and commentary on the psychedelics space: from business and drug development through to policy reform and culture.

Already a member? Log In

✓   Regular Bulletins covering key topics and trends in the psychedelics space
✓   Regular articles and deep dives across psychedelic research, policy and business
✓   Interviews with insiders
✓   Monthly interactive database and commentary on psychedelic patents
✓   Quick-take analysis of major developments
✓   A Library of primers and explainers
✓   Access to our full back catalogue

Learn more about Pα+

SkinTE by RegenETP for Diabetic Foot Ulcers: Likelihood of Approval

SkinTE is under clinical development by RegenETP and currently in Phase III for Diabetic Foot Ulcers.

May 20, 2024

Study uncovers the role of mGluR1 in pruning early neural connections

Not everything in the brain is meant to last. As our brains assemble, trillions of neural connections have to be built or torn down at

July 1, 2024

The lone Democrat willing to weaken Medicare’s power to negotiate drug prices

WASHINGTON — Two Republican lawmakers who introduced legislation to water down the Inflation Reduction Act’s Medicare drug price negotiation program managed to find themselves a

February 5, 2024

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.